First-in-Human Randomized Controlled Pilot Trial of a Maxillofacial Drug Delivery Platform for Low-Dose Systemic...

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Biomedical Engineering

Background:

• Evaluating a novel maxillofacial drug delivery platform for systemic metronidazole administration.
• This route bypasses gastrointestinal absorption and first-pass hepatic metabolism.
• Pilot randomized controlled trial (RCT) design.

Purpose of the Study:

• To assess the safety and efficacy of a novel maxillofacial drug delivery platform.
• To evaluate early systemic exposure of metronidazole via a maxillofacial route.
• To compare systemic exposure with standard oral metronidazole delivery.

Main Methods:

• Pilot randomized controlled trial (RCT) with 20 patients undergoing endodontic therapy.
• Comparison between oral metronidazole (400 mg) and maxillofacial platform (5 mg).
• Plasma metronidazole concentrations quantified using high-performance liquid chromatography (HPLC) at 15 and 30 minutes.

Main Results:

• Significant early systemic exposure observed with the maxillofacial platform, even at an 80-fold lower dose.
• Dose-normalized AUC (DN AUC) analysis confirmed robust findings.
• No local or systemic adverse events were reported in either group.

Conclusions:

• The maxillofacial drug delivery platform shows potential for safe and rapid systemic drug delivery.
• Low-dose systemic drug administration is feasible via this novel route.
• Further research may explore broader applications of this drug delivery technology.